Loading organizations...
Alida Capital International operates as an angel investment syndicate, providing seed-stage capital and strategic support to promising biopharmaceutical companies. The firm identifies and nurtures early-stage ventures within the life sciences sector, accelerating their development from concept through market entry with practical guidance.
Established in Edinburgh, United Kingdom, in 2009, Alida Capital International was formed by a collective of business angels. They recognized a significant need for specialized early-stage investment and mentorship within the burgeoning biopharmaceutical industry, creating a syndicate focused on driving scientific and commercial progress.
The firm's portfolio comprises nascent biopharmaceutical enterprises, which leverage Alida Capital International’s resources to advance research, development, and market strategies. Alida Capital International envisions itself as a catalyst for growth, supporting new therapies and medical solutions by backing innovative companies poised for impact in healthcare.
Alida Capital International has 2 tracked investments across 1 company. The latest tracked deal is $57.0M Series B in NuCana in March 2014.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2014 | NuCana | $57.0M Series B | Sofinnova Investments | Pivotal BioVenture Partners, SR ONE, Gerald Chan, Scottish Enterprise, Sofinnova Partners |
| Nov 29, 2011 | NuCana | $10.5M Series A | Sofinnova Partners | Morningside Ventures, Scottish Enterprise |